BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37481865)

  • 1. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.
    Padovan M; Maccari M; Bosio A; De Toni C; Vizzaccaro S; Cestonaro I; Corrà M; Caccese M; Cerretti G; Zagonel V; Lombardi G
    Eur J Cancer; 2023 Sep; 191():112959. PubMed ID: 37481865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.
    Bayle A; Belcaid L; Aldea M; Vasseur D; Peyraud F; Nicotra C; Geraud A; Sakkal M; Seknazi L; Cerbone L; Blanc-Durand F; Hadoux J; Mosele F; Tagliamento M; Bernard-Tessier A; Verret B; Smolenschi C; Clodion R; Auger N; Romano PM; Gazzah A; Camus MN; Micol J; Caron O; Hollebecque A; Loriot Y; Besse B; Lacroix L; Rouleau E; Ponce S; Soria JC; Barlesi F; Andre F; Italiano A
    Ann Oncol; 2023 Apr; 34(4):389-396. PubMed ID: 36709039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma.
    Lazaridis L; Schmidt T; Oster C; Blau T; Pierscianek D; Siveke JT; Bauer S; Schildhaus HU; Sure U; Keyvani K; Kleinschnitz C; Stuschke M; Herrmann K; Deuschl C; Scheffler B; Kebir S; Glas M
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3513-3526. PubMed ID: 35953681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
    Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
    J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.
    Lim-Fat MJ; Youssef GC; Touat M; Iorgulescu JB; Whorral S; Allen M; Rahman R; Chukwueke U; McFaline-Figueroa JR; Nayak L; Lee EQ; Batchelor TT; Arnaout O; Peruzzi PP; Chiocca EA; Reardon DA; Meredith D; Santagata S; Beroukhim R; Bi WL; Ligon KL; Wen PY
    Neuro Oncol; 2022 Jul; 24(7):1140-1149. PubMed ID: 34878541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients.
    Melisi D; Cavaliere A; Gobbo S; Fasoli G; Allegrini V; Simionato F; Gaule M; Casalino S; Pesoni C; Zecchetto C; Merz V; Mambrini A; Barbi E; Girelli R; Giardino A; Frigerio I; Scalamogna R; Avitabile A; Castellani S; Milella M; Butturini G
    Pancreatology; 2021 Apr; ():. PubMed ID: 33896692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
    Huang CC; Tsai YF; Liu CY; Chao TC; Lien PJ; Lin YS; Feng CJ; Chiu JH; Hsu CY; Tseng LM
    BMC Cancer; 2021 Feb; 21(1):199. PubMed ID: 33632156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study.
    Bosio A; Cerretti G; Padovan M; Caccese M; Denaro L; Chioffi F; Della Puppa A; Aldegheri V; Guarneri V; Zagonel V; Lombardi G
    Clin Oncol (R Coll Radiol); 2023 May; 35(5):e319-e327. PubMed ID: 36858930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement.
    Colomer R; Miranda J; Romero-Laorden N; Hornedo J; González-Cortijo L; Mouron S; Bueno MJ; Mondéjar R; Quintela-Fandino M
    EClinicalMedicine; 2023 Jun; 60():102029. PubMed ID: 37304496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.
    Mulet Margalef N; Castillo C; Mosteiro M; Pérez X; Aguilar S; Ruíz-Pace F; Gil M; Cuadra C; Ruffinelli JC; Martínez M; Losa F; Soler G; Teulé À; Castany R; Gallego R; Ruíz A; Garralda E; Élez E; Vivancos A; Tabernero J; Salazar R; Dienstmann R; Santos Vivas C
    Mol Oncol; 2023 Sep; 17(9):1908-1916. PubMed ID: 37097008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma.
    Adilijiang A; Hirano M; Okuno Y; Aoki K; Ohka F; Maeda S; Tanahashi K; Motomura K; Shimizu H; Yamaguchi J; Wakabayashi T; Natsume A
    Molecules; 2019 Aug; 24(17):. PubMed ID: 31443404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma.
    Verdaguer H; Saurí T; Acosta DA; Guardiola M; Sierra A; Hernando J; Nuciforo P; Miquel JM; Molero C; Peiró S; Serra-Camprubí Q; Villacampa G; Aguilar S; Vivancos A; Tabernero J; Dienstmann R; Macarulla T
    Clin Cancer Res; 2022 Apr; 28(8):1662-1671. PubMed ID: 35042699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.
    Ma LX; Espin-Garcia O; Bedard PL; Stockley T; Prince R; Mete O; Krzyzanowska MK
    Thyroid; 2022 Jun; 32(6):657-666. PubMed ID: 35262412
    [No Abstract]   [Full Text] [Related]  

  • 15. Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis.
    Palande V; Siegal T; Detroja R; Gorohovski A; Glass R; Flueh C; Kanner AA; Laviv Y; Har-Nof S; Levy-Barda A; Viviana Karpuj M; Kurtz M; Perez S; Raviv Shay D; Frenkel-Morgenstern M
    Mol Oncol; 2022 May; 16(10):2098-2114. PubMed ID: 34875133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation profile in liquid biopsy tested by next generation sequencing in Mexican patients with non-small cell lung carcinoma and its impact on survival.
    Martínez-Herrera JF; Sánchez Domínguez G; Juárez-Vignon Whaley JJ; Carrasco-Cara Chards S; López Vrátný C; Guzmán Casta J; Riera Sala RF; Alatorre-Alexander JA; Seidman Sorsby A; Cruz Zermeño M; Conde Flores E; Flores-Mariñelarena RR; Sánchez-Ríos CP; Martínez-Barrera LM; Gerson-Cwilich R; Santillán-Doherty P; Jiménez López JC; López Hernández W; Rodríguez-Cid JR
    J Thorac Dis; 2024 Jan; 16(1):161-174. PubMed ID: 38410597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Evolution of
    Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ
    J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
    Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
    Moreira A; Masliah-Planchon J; Callens C; Vacher S; Lecerf C; Frelaut M; Borcoman E; Torossian N; Ricci F; Hescot S; Sablin MP; Tresca P; Loirat D; Melaabi S; Trabelsi-Grati O; Pierron G; Gentien D; Bernard V; Vincent Salomon A; Servant N; Bieche I; Le Tourneau C; Kamal M
    Eur J Cancer; 2019 Nov; 121():202-209. PubMed ID: 31593830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
    Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
    Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.